Market Cap 835,000.00
Revenue (ttm) 0.00
Net Income (ttm) -24.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -2.88
Volume 890,100
Avg Vol 20,159,402
Day's Range N/A - N/A
Shares Out 52.84M
Stochastic %K 0%
Beta 3.37
Analysts Hold
Price Target N/A

Company Profile

Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel...

Industry: Biotechnology
Sector: Healthcare
Phone: 353 1 903 8354
Address:
3 Dublin Landings, North Wall Quay, Dublin, Ireland
Latest News on ITRMF
No data available.